Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials Giulia Renda, MD, PhD, Marta.

Slides:

Advertisements

Similar presentations

R4 문정락 / IC prof. 김진배 Lancet Haematol 2015;2: e150–59.

Advertisements

Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated.

The Epidemic of the 20th Century: Coronary Heart Disease

Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta- Analysis of Randomized Trials Sripal Bangalore, MD, MHA, Bora Toklu,

New-onset Atrial Fibrillation Predicts Heart Failure Progression

Benefits and risks of using clopidogrel before coronary artery bypass surgery: Systematic review and meta-analysis of randomized trials and observational.

Alfred A. Bartolucci, PhD, Michal Tendera, MD, George Howard, DrPH

Russell D. Hull, MBBS, MSc, Graham F. Pineo, MD, Rollin F

Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation: Time for a reappraisal Gregory.

Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study Torben Bjerregaard Larsen, MD,

An Unusual Cause of Leg Ulcerations

Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Chirag Bavishi, MD, MPH,

Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II Menno V. Huisman,

Impact of More Restrictive Blood Transfusion Strategies on Clinical Outcomes: A Meta- analysis and Systematic Review Shelley R. Salpeter, MD, Jacob S.

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study Torben Bjerregaard Larsen, MD,

Volume 15, Issue 1, Pages (January 2018)

Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction Stein Ørn, MD, John G.F. Cleland, MD, Matti.

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

Maureen M. Okam, MD, MPH, Todd A. Koch, Minh-Ha Tran, DO

Matthew A. Cavender, MD, MPH, Benjamin M

Introduction The American Journal of Medicine

Matthew I. Worthley, MBBS, PhD, FRACP, Fiona M

Systematic Review and Meta-analysis of Adverse Events of Low-dose Aspirin and Clopidogrel in Randomized Controlled Trials Kenneth R. McQuaid, MD, Loren.

Trends in Stroke Rates, Risk, and Outcomes in the United States, 1988 to 2008 Margaret C. Fang, MD, MPH, Marcelo Coca Perraillon, MA, Kaushik Ghosh, PhD,

Do higher-risk patients benefit from off-pump coronary artery bypass grafting? Evidence from an ecologic analysis of randomized trials Oliver Kuss, PhD,

Wandering Acute Myocardial Infarction

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation Giulia Renda, MD, PhD, Marco.

SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation Pilar Gallego, MD, PhD, Vanessa Roldán,

Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease Nina Raju, MD, MsC, Magdalena Sobieraj-Teague, MBBS, Jack Hirsh, MD,

Thomas E. MacMillan, MD, MSc, Terence Tang, MD, Rodrigo B

Trend in Mortality after Stroke with Atrial Fibrillation

The Effect of a Statewide Smoking Ordinance on Acute Myocardial Infarction Rates Paul Basel, BS, Becki Bucher Bartelson, PhD, Marie Claire Le Lait, MS,

The Epidemic of the 20th Century: Coronary Heart Disease

Russell D. Hull, MBBS, MSc, Graham F. Pineo, MD, Rollin F

Age and Gender Differences in Quality of Care and Outcomes for Patients with ST- segment Elevation Myocardial Infarction Sripal Bangalore, MD, MHA, Gregg.

Methylene Chloride Intoxication Treated With Hyperbaric Oxygen Therapy

The Reply The American Journal of Medicine

Hong-Tao Tie, MD, Rui Shi, MD The American Journal of Medicine

Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta- Analysis of Randomized Trials Sripal Bangalore, MD, MHA, Bora Toklu,

History of Thyroid Disorders in Relation to Clinical Outcomes in Atrial Fibrillation Helene Bruere, MD, Laurent Fauchier, MD, PhD, Anne Bernard Brunet,

Gout in African Americans

Cardiovascular Risks of Exogenous Testosterone Use Among Men: A Systematic Review and Meta-Analysis G. Caleb Alexander, MD, MS, Geetha Iyer, MBBS, Eleanor.

Truman J. Milling, MD, Alex C. Spyropoulos, MD

Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin Keitaro Senoo, MD, Marco Proietti,

When Guidelines Cause Hypertension

Isla M. Ogilvie, PhD, Nick Newton, PhD, Sharon A

Yader Sandoval, MD, Stephen W. Smith, MD, Sara A

Clinical Outcomes After Treatment of Cocaine-Induced Chest Pain with Beta-Blockers: A Systematic Review and Meta-Analysis Kevin Bryan Lo, MD, Hafeez.

Usefulness of CHADS2 and CHA2DS2-VASc Scores in the Prediction of New-Onset Atrial Fibrillation: A Population-Based Study Walid Saliba, MD, MPH, Naomi.

MATCH Results: Implications for the Internist

Age Differences in Treatment and Control of Hypertension in US Physician Offices, : A Serial Cross-sectional Study Anna Gu, MD, PhD, Yu Yue,

Role of Niacin in Current Clinical Practice: A Systematic Review

Effect of Folic Acid, with or without Other B Vitamins, on Cognitive Decline: Meta- Analysis of Randomized Trials David S. Wald, MA, MRCP, MD, Anuradhani.

Long-term Effect of Chronic Oral Anticoagulation with Warfarin after Acute Myocardial Infarction Salman A. Haq, MD, John F. Heitner, MD, Terrence J.

One-way Versus Two-way Text Messaging on Improving Medication Adherence: Meta- analysis of Randomized Trials David S. Wald, MD, FRCP, Shahena Butt, MSc,

National Trends in Ambulatory Oral Anticoagulant Use

The American Journal of Medicine

Concomitant Use of Direct Oral Anticoagulants with Antiplatelet Agents and the Risk of Major Bleeding in Patients with Nonvalvular Atrial Fibrillation

Sister Mary Joseph's Node

The American Journal of Medicine

Combining Antiplatelet and Antithrombotic Therapy (Triple Therapy): What Are the Risks and Benefits? Luis Alejandro Asencio, MD, Jennifer J. Huang, DO,

Screening and Treatment of Vitamin D Deficiency on Hospital Admission: Is There a Benefit for Medical Inpatients? Lena Grädel, MD, Meret Merker, BMSc,

Nicholas Z. Kerin, MD, Sony Jacob, MD The American Journal of Medicine

Rebecca D. Chason, Joan S. Reisch, PhD, Don C. Rockey, MD

Higher Cardiovascular Disease Prevalence and Mortality among Younger Blacks Compared to Whites Stacey Jolly, MD, MS, Eric Vittinghoff, PhD, Arpita Chattopadhyay,

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation Giulia Renda, MD, PhD, Marco.

Falls in Older Adults: Risk Assessment, Management and Prevention

Toward a More Responsible News Media

Preoperative Thienopyridine Use and Outcomes after Surgery: A Systematic Review Anita G. Au, MD, Sumit R. Majumdar, MD MPH, Finlay A. McAlister, MD MSc

Presentation transcript:

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials Giulia Renda, MD, PhD, Marta di Nicola, PhD, Raffaele De Caterina, MD, PhD The American Journal of Medicine Volume 128, Issue 9, Pages 1007-1014.e2 (September 2015) DOI: 10.1016/j.amjmed.2015.03.034 Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 1 RR and 95% CI of all treatment arms in the phase III trials comparing a non-vitamin K antagonist oral anticoagulants with warfarin for the overall composite outcome including unweighed ischemic stroke + systemic embolism + myocardial infarction + hemorrhagic stroke + adjusted major bleeding (major bleeding minus hemorrhagic stroke). NOAC = non-vitamin K antagonist oral anticoagulant. The American Journal of Medicine 2015 128, 1007-1014.e2DOI: (10.1016/j.amjmed.2015.03.034) Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure 2 Net clinical benefit and 95% CI of all treatment arms of non-vitamin K antagonist oral anticoagulants versus warfarin tested in phase III clinical trials for the weighed composite outcome of ischemic stroke + systemic embolism + myocardial infarction + hemorrhagic stroke + adjusted major bleeding (major bleeding minus hemorrhagic stroke). Net clinical benefit is expressed as ischemic stroke equivalents prevented per 100 person-years using ischemic stroke as the reference event (weight = 1). CI = confidence interval; IS = ischemic stroke; NNT = number needed to treat (to prevent all grouped events included in the net clinical benefit evaluation, per year of treatment); NOAC = non-vitamin K antagonist oral anticoagulant. The American Journal of Medicine 2015 128, 1007-1014.e2DOI: (10.1016/j.amjmed.2015.03.034) Copyright © 2015 Elsevier Inc. Terms and Conditions

Figure E1 RR and 95% CI of all treatment arms versus warfarin for the composite outcome including unweighed ischemic stroke + systemic embolism + myocardial infarction + hemorrhagic stroke + adjusted major bleeding (major bleeding minus hemorrhagic stroke) + all-cause death in the 4 phase III trials of a non-vitamin K antagonist oral anticoagulant versus warfarin in nonvalvular atrial fibrillation. Contrary to the analyses presented in the article, the current analysis has to be considered exploratory, because it may include nonmutually exclusive events. NOAC = non-vitamin K antagonist oral anticoagulant. The American Journal of Medicine 2015 128, 1007-1014.e2DOI: (10.1016/j.amjmed.2015.03.034) Copyright © 2015 Elsevier Inc. Terms and Conditions